Schizophrenia: all 3,539 studies
Page 5 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.
- Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar DisorderRecruitingNCT05025605Phase 1
- Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsEnrolling by invitationNCT04987229Phase 3
- Combination of NMDA-enhancing and Antioxidant Treatments for SchizophreniaRecruitingNCT04959201Phase 2
- Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric DiseaseRecruitingNCT04946916Not applicable
- Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological VulnerabilityRecruitingNCT04945278Not applicable
- Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental IllnessRecruitingNCT04940663Not applicable
- Combination of NMDA-enhancing and Anti-inflammatory Treatments for SchizophreniaRecruitingNCT04917302Phase 2
- Effectiveness of Trauma Therapy in Patients With PTSD and Comorbid Psychotic DisorderRecruitingNCT04911010Not applicable
- Cognitive Effects of Adjuvant Vortioxetine in Early SchizophreniaRecruitingNCT04895488Phase 2/3
- Acetazolamide for Treatment Resistant SchizophreniaRecruitingNCT04887792Phase 1/2
- Examining tDCS Effect on Cannabis Use Disorder in Patients With SchizophreniaRecruitingNCT04871048Not applicable
- Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity BiotypesRecruitingNCT04853485Not applicable
- Medial-prefrontal Enhancement During Schizophrenia Systems ImagingRecruitingNCT04807530Not applicable
- fMRI-based Neurofeedback to Relieve Drug-resistant Auditory HallucinationsRecruitingNCT04798131Not applicable
- Monotherapy of an NMDA Enhancer for SchizophreniaRecruitingNCT04745143Phase 2
- Yoga-based Group Intervention (YoGI) for In-patients With Schizophrenia Spectrum DisordersRecruitingNCT04730518Not applicable
- Translational Investigation of the Glutamatergic and GABAergic System in SchizophreniaRecruitingNCT04655235
- Metacognitive Training as a Serious GameRecruitingNCT04631939Not applicable
- Effect of Neuroplasticity Modulation in tDCS Treatment Response Among Schizophrenia Patients With Auditory HallucinationRecruitingNCT04629352Not applicable
- Cognitive Remediation in Forensic Mental Health CareRecruitingNCT04610697Not applicable
- Neuropsychological Assessment of Remediation for Cognitive Impairments in SchizophreniaRecruitingNCT04608032Not applicable
- CLOZAPINE Response in Biotype-1RecruitingNCT04580134Phase 4
- "Extended" (Alternate Day) Antipsychotic DosingRecruitingNCT04478838Phase 4
- Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With SchizophreniaRecruitingNCT04452175Not applicable
- Time and Virtual Reality in Schizophrenia and Bipolar DisorderRecruitingNCT04432116Not applicable
- Cognitive Training for Emotion Regulation in Psychotic DisordersRecruitingNCT04414215Not applicable
- Dimensional and Developmental Profiles of Psychosis in Children and AdolescentsRecruitingNCT04370730Not applicable
- Assessment of the Efficacy of a Fatigue Management Therapy in SchizophreniaNot yet recruitingNCT04332601Not applicable
- Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System InvolvementEnrolling by invitationNCT04323566Phase 2
- Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness)RecruitingNCT04321759Not applicable
- Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy VolunteersRecruitingNCT04300946
- Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric PopulationsRecruitingNCT04296604Not applicable
- Study of Electrophysiological Markers Related to the Cognitive and Affective Processes Behind Empathic Behaviour in Schizophrenic Spectrum DisorderRecruitingNCT04278339Not applicable
- Effects of Brain Stimulation on Cognition, Oscillations and GABA Levels in SchizophreniaRecruitingNCT04267003Not applicable
- French Source-monitoring TaskRecruitingNCT04237155Not applicable
- Synbiotic Compound to Reduce Symptoms of SchizophreniaRecruitingNCT04226898Phase 2
- Brain Imaging of Cognition Inn Schizophrenia and DepressionRecruitingNCT04159662
- Cognitive Behavioral Therapy for Insomnia (CBT-I) in Schizophrenia(SLEEPINS)RecruitingNCT04144231Not applicable
- Bazedoxifene -Treatment for Women With SchizophreniaRecruitingNCT04113993Phase 4
- Virtual Reality Avatar Therapy for People Hearing VoicesRecruitingNCT04099940Not applicable
- Comparaison of Avatar Therapy to Cognitive Behavioral Therapy in Schizophrenia With Treatment Refractory HallucinationsRecruitingNCT04054778Not applicable
- Imaging Synapses With [11C] UCB-J in the Human BrainRecruitingNCT04038840Phase 1
- Early-Phase Schizophrenia: Practice-based Research to Improve OutcomesRecruitingNCT04004364
- Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early SchizophreniaNot yet recruitingNCT03974620Not applicable
- Ocrelizumab for Psychosis by AutoimmunityRecruitingNCT03971487Phase 1/2
- Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With SchizophreniaRecruitingNCT03911726Not applicable
- Ketogenic Diet for Psychotic DisordersRecruitingNCT03873922Not applicable
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaRecruitingNCT03817502Phase 3
- Cromoglicate Adjunctive Therapy for Outpatients With SchizophreniaRecruitingNCT03794076Phase 1/2
- Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic DisordersRecruitingNCT03649581Not applicable
- Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis UseRecruitingNCT03601026Not applicable
- Bromocriptine for Patients With Schizophrenia and PrediabetesNot yet recruitingNCT03575000Phase 4
- From Brain Currents to Interpersonal Flow: Investigating the Social Processing Stream of SchizophreniaNot yet recruitingNCT03543553
- Semantic and Syntactic Computerized Analysis of Free SpeechRecruitingNCT03525054
- Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as CorrelatesRecruitingNCT03495024Phase 4
- Cerebellar Stimulation and Cognitive ControlRecruitingNCT03217110Not applicable
- An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in AdultsRecruitingNCT03094429Phase 2/3
- Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation TreatmentRecruitingNCT02916810Not applicable
- Immuno-Genetic, Inflammation, Retro-Virus, EnvironmentRecruitingNCT02878408Not applicable
- Tocilizumab in SchizophreniaRecruitingNCT02874573Phase 1
- Siltuximab in SchizophreniaRecruitingNCT02796859Phase 1/2
- Structural and Functional Correlates of Clinical Response to rTMS Treatment in Schizophrenia Patients With Resistant Auditory HallucinationsRecruitingNCT02755623Not applicable
- Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support StrategiesRecruitingNCT02670447
- An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With SchizophreniaRecruitingNCT02640911
- Switching From Twice-Daily to Once-Daily Clozapine Dosing in SchizophreniaRecruitingNCT02639702Phase 4
- Neuronal Effects of Exercise in SchizophreniaRecruitingNCT02455193Not applicable
- Skills for WellnessRecruitingNCT01980147Not applicable
- Integrated Care in Psychotic Disorders With Severe Mental IllnessRecruitingNCT01888627Not applicable
- Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) ScanningRecruitingNCT01730781
- Database Registry for Neural Network Biomarkers in PsychosisRecruitingNCT01409109
- Brain Health and Exercise in SchizophreniaRecruitingNCT01392885
- Zyprexa® Relprevv™ Patient Care ProgramEnrolling by invitationNCT01088386
- Psychiatric Genotype/Phenotype Project RepositoryEnrolling by invitationNCT00762866
- Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in SchizophreniaCompletedNCT07190352Not applicableResults posted
- Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With SchizophreniaCompletedNCT06572449Phase 3Results posted
- A Trial to Assess a Wearable Patch's Functioning to Detect Medication IngestionCompletedNCT06372210Not applicableResults posted
- Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective DisorderCompletedNCT06319170Phase 1Results posted
- Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With SchizophreniaCompletedNCT06253546Phase 1Results posted
- Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaCompletedNCT06179108Phase 2Results posted
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaCompletedNCT06107803Phase 1Results posted
- CAE for Poorly Adherent Individuals With SchizophreniaCompletedNCT06061952Not applicableResults posted
- Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar DisorderCompletedNCT06041646Phase 4Results posted
- Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With SchizophreniaCompletedNCT06036108Phase 1Results posted
- Horyzons: Implementation and Integration in Clinical PracticeTerminatedNCT06002958Not applicableResults posted
- A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)CompletedNCT05953740Phase 1Results posted
- A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 SchizophreniaCompletedNCT05919823Phase 3Results posted
- iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic DisordersCompletedNCT05899348Not applicableResults posted
- A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)CompletedNCT05893862Phase 1Results posted
- Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 4Results posted
- Young Adults With Violent Behavior During Early Psychosis (Aim 2)CompletedNCT05756855Not applicableResults posted
- The Efficacy of Neural Stimulation in Individuals With SchizophreniaCompletedNCT05746494Not applicableResults posted
- Motivation Skills Training for SchizophreniaCompletedNCT05746455Not applicableResults posted
- An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic MedicationCompletedNCT05741528Phase 3Results posted
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With SchizophreniaCompletedNCT05693935Phase 3Results posted
- C-Cog in Early Course Schizophrenia StudyTerminatedNCT05662306Phase 4Results posted
- TMS Related Biomarker AssessmentsCompletedNCT05660018Not applicableResults posted
- Focused Ultrasound Modulation of the Globus Pallidus Interna in SchizophreniaCompletedNCT05643196Phase 2Results posted
- An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of SchizophreniaTerminatedNCT05643170Phase 3Results posted
- A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic MedicationCompletedNCT05628103Phase 3Results posted
- The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.CompletedNCT05623228Phase 2Results posted